Objective The efficacy and safety of Jinlong Capsule combined with chemoradiotherapy on liver metastases patients.

Methods A computer-based search was conducted for the literature about the randomized controlled trials of Jinlong Capsule in the treatment of liver metastases in PubMed, CNKI, Weipu, Wanfang and CBM databases according to the Cochrane guidelines. Two evaluators extracted and evaluated the data according to the uniform standard independently. The analysis was performed using RevMan5.3 software.

Results Eight studies were eventually included, involving 504 patients. The effective rate of Jinlong capsule (P=0.0006) and the improvement of immune function were significantly better than the control group (CD₃:P=0.0003, CD₄:P < 0.00001, CD₄/CD₈:P < 0.00001), however, the effect on CD₈ was not significantly different (P=0.73). The incidence of digestive system adverse reactions nausea and vomiting(P=0.01) and abdominal pain(P=0.05) were significantly lower than that in the control group.

Conclusion Jinlong Capsule could improve the immune function of patients, reduce side effects, improve the quality of life and has obvious auxiliary treatment effect on liver metastases.